^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | veliparib (ABT-888) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
Published date:
06/15/2021
Excerpt:
...metastatic or locally advanced unresectable HER2-negative breast cancer and deleterious or suspected deleterious gBRCA1 or gBRCA2 mutations...patients had received ≥1 dose of open-label crossover veliparib monotherapy after progression...Median PFS was numerically longer for the BRCA2 [4.2 months (95% CI, 2.1–7.3)] and hormone receptor–positive [2.7 months (95% CI, 2.1–6.0)] subgroups...within each subgroup, there were patients who were progression free for 12 months or longer (BRCA1, 2 patients; BRCA2, 3 patients; TNBC, 3 patients; hormone receptor positive, 2 patients...
DOI:
10.1158/1078-0432.CCR-21-0748
Trial ID:
